In the last few days in the world of diabetes has triggered an earthquake: a study published June 26 in Diabetologia, the journal of EASD, has highlighted a possible carcinogenic effect of Lantus, that insulin glargine. The famous and expensive insulin similar that allows those who have diabetes to control their blood sugar through a basal rate of 24 hours (or almost) with one injection per day would therefore be dangerous to your health, even if the conditional is a must .
A survey of 127,000 patients with diabetes in Germany have found that people who regularly use the Lantus has 31% more chance of developing cancer over a period of one year and a half, and that the risk is proportional to the amount of Lantus taken daily. Similar studies conducted in Sweden, Scotland and the United Kingdom have partially confirmed the results, although there are some conflicting data. The Food and Drug Administration has opened an investigation to pursue the matter.
This is a preliminary research that certainly goes in-depth with further study before arriving at a definitive answer, as admitted by the authors of the scientific publication. However, there was great confusion triggered by the news, along with the sensation exploded in diabetes. But above all is the great dismay that crosses many people with diabetes who use that insulin, which ask for certain answers and quick fixes. It is important to remember, however, that patients treated with Lantus must not discontinue treatment without the consent of your physician diabetologist.
Even from the financial point of view there has been a collapse in stock price Sanofi-Aventis: the French pharmaceutical company that produces the Lantus has lost more than 7% in one day of publication of the study. Sanofi Aventis is the same corporation that only a few days before the outbreak of the "scandal Lantus" announced the production of a vaccine against the famous "swine flu", also known as swine flu.
Immediately after the stock market crash, the Sanofi Aventis has seen fit to issue a number of press, with which it aims to ensure that in fact the Lantus is completely safe and that there is no link with cancer, challenging the method used by the researchers in the study recently published. The question that arises is: "who" wanted to reassure the leaders of Sanofi Aventis? Physicians who prescribe Lantus? Or maybe the shareholders who buy stocks? The fear is that we forget the people. Because the money and interests that revolve around these topics are many, indeed many, and I would not want the biggest concern was that an effort to secure sales and capital, before the actual safety of the drug. But diabetics are really more important than money?
Doubts are also personally because I had heard rumors about the carcinogenicity of Lantus already 2 years ago, although at that time no one spoke, and there was nothing confirmed about it, but because the news came just now, conquering the most important media and newspapers worldwide? Perhaps because of the noise amplified by the stock market crash? Or maybe because the economic interests demanded that things were going well?
You have to pretend rather than at the center of the issue there is the person with diabetes and his health. Rather than reassure "a priori", it would be good for all, including Sanofi Aventis, would take in hand the results of the study seriously, and to flesh out urgently with new research, in order to give a definite answer on Lantus and rapid, with the hope that This insulin is actually safe for all who use it. We hope that this is the path taken by all companies, associations of diabetes, and scientific bodies. Emphasizing the centrality of the person before everything else because it serves the ethical economy, especially in pharmacology, where it comes in the lives of people. We await answers.
Link to the article of the study on Lantus and cancer published by the European Association for the Study of Diabetes: www.diabetologia-journal.org/cancer.html
Site Response Sanofi Aventis on the safety of Lantus: www.factsaboutlantus.com